FMR1 and fragile X syndrome: Therefore, FMRP targeted signaling molecules not only provide therapeutic strategies for fragile X syndrome and other ASDs (Darnell and Klann, 2013; Santini and Klann, 2014), but may serve as potential targets for treatment of AD.